517 related articles for article (PubMed ID: 25704982)
1. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.
Kool M; Fontein DB; Meershoek-Klein Kranenbarg E; Nortier JW; Rutgers EJ; Marang-van de Mheen PJ; van de Velde CJ
Breast; 2015 Jun; 24(3):224-9. PubMed ID: 25704982
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
[TBL] [Abstract][Full Text] [Related]
4. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
Ferreira AR; Di Meglio A; Pistilli B; Gbenou AS; El-Mouhebb M; Dauchy S; Charles C; Joly F; Everhard S; Lambertini M; Coutant C; Cottu P; Lerebours F; Petit T; Dalenc F; Rouanet P; Arnaud A; Martin A; Berille J; Ganz PA; Partridge AH; Delaloge S; Michiels S; Andre F; Vaz-Luis I
Ann Oncol; 2019 Nov; 30(11):1784-1795. PubMed ID: 31591636
[TBL] [Abstract][Full Text] [Related]
5. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
Schwentner L; Harbeck N; Singer S; Eichler M; Rack B; Forstbauer H; Wischnik A; Scholz C; Huober J; Friedl TW; Weissenbacher T; Härtl K; Kiechle M; Janni W; Fink V
Breast; 2016 Jun; 27():69-77. PubMed ID: 27054751
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
8. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
9. [Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study].
Liang XF; Ma DC; Ding ZY; Liu ZZ; Guo F; Liu L; Yu HY; Han YL; Xie XD
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):764-8. PubMed ID: 24378099
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women.
Browall M; Ahlberg K; Karlsson P; Danielson E; Persson LO; Gaston-Johansson F
Eur J Oncol Nurs; 2008 Jul; 12(3):180-9. PubMed ID: 18343197
[TBL] [Abstract][Full Text] [Related]
11. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
Kornblith AB; Lan L; Archer L; Partridge A; Kimmick G; Hudis C; Winer E; Casey R; Bennett S; Cohen HJ; Muss HB
J Clin Oncol; 2011 Mar; 29(8):1022-8. PubMed ID: 21300923
[TBL] [Abstract][Full Text] [Related]
12. Quality of life of Croatian breast cancer patients receiving adjuvant treatment--comparison to long-term breast cancer survivors.
Murgić J; Soldić Z; Vrljić D; Samija I; Kirac I; Bolanca A; Kusić Z
Coll Antropol; 2012 Dec; 36(4):1335-41. PubMed ID: 23390830
[TBL] [Abstract][Full Text] [Related]
13. Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; Liefers GJ; Nortier JWR; Rutgers EJT; Seynaeve CM; van de Velde CJH;
Eur J Cancer; 2018 May; 95():59-67. PubMed ID: 29635145
[TBL] [Abstract][Full Text] [Related]
14. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
Joly F; Espié M; Marty M; Héron JF; Henry-Amar M
Br J Cancer; 2000 Sep; 83(5):577-82. PubMed ID: 10944595
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.
Taira N; Iwata H; Hasegawa Y; Sakai T; Higaki K; Kihara K; Yamaguchi T; Ohsumi S; Shimozuma K; Ohashi Y
Breast Cancer Res Treat; 2014 May; 145(1):155-64. PubMed ID: 24692082
[TBL] [Abstract][Full Text] [Related]
16. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Fontein DB; Nortier JW; Liefers GJ; Putter H; Meershoek-Klein Kranenbarg E; van den Bosch J; Maartense E; Rutgers EJ; van de Velde CJ
Eur J Surg Oncol; 2012 Feb; 38(2):110-7. PubMed ID: 22172646
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
Groenvold M; Fayers PM; Petersen MA; Mouridsen HT
Breast Cancer Res Treat; 2006 Aug; 98(3):275-84. PubMed ID: 16541325
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
20. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
